Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies

Bibliographic Details
Title: Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies
Authors: Chin-King Looi, Ee-Mun Loo, Heng-Chee Lim, Yik-Ling Chew, Kok-Yong Chin, Shiau-Chuen Cheah, Bey Hing Goh, Chun-Wai Mai
Source: Frontiers in Immunology, Vol 15 (2024)
Publisher Information: Frontiers Media S.A., 2024.
Publication Year: 2024
Collection: LCC:Immunologic diseases. Allergy
Subject Terms: nasopharyngeal carcinoma, stem cell, chimeric antigen receptor (CAR)-T cell, engineered T cell receptor-T (TCR-T) cell, tumour-infiltrating lymphocytes (TIL), natural killer (Nk) cell, Immunologic diseases. Allergy, RC581-607
More Details: Nasopharyngeal carcinoma (NPC) is a distinct malignancy of the nasopharynx and is consistently associated with the Epstein-Barr virus (EBV) infection. Its unique anatomical location and complex aetiology often result in advanced-stage disease at first diagnosis. While radiotherapy (RT) and chemotherapy have been the mainstays of treatment, they often fail to prevent tumour recurrence and metastasis, leading to high rates of treatment failure and mortality. Recent advancement in cell-based therapies, such as chimeric antigen receptor (CAR)-T cell therapy, have shown great promise in hematological malignancies and are now being investigated for NPC. However, challenges such as targeting specific tumour antigens, limited T cell persistence and proliferation, and managing treatment-related toxicities must be addressed. Extensive research is needed to enhance the effectiveness and safety of these therapies, paving the way for their integration into standard clinical practice for better management of NPC and a better quality of life for human health.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1664-3224
Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1484535/full; https://doaj.org/toc/1664-3224
DOI: 10.3389/fimmu.2024.1484535
Access URL: https://doaj.org/article/4cef446874884264a4edf8ef291c940c
Accession Number: edsdoj.4cef446874884264a4edf8ef291c940c
Database: Directory of Open Access Journals
More Details
ISSN:16643224
DOI:10.3389/fimmu.2024.1484535
Published in:Frontiers in Immunology
Language:English